MRV Research

Myriad Genetics (MYGN) Reports Publication of Positive myPath Melanoma Data

MRV Research, Of Interest

Myriad Genetics announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy.1 Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.

Read More

National Cancer Institute grant enables Rutgers CINJ investigators to explore melanoma metastasis

The mechanism by which small cellular vesicles promote melanoma metastasis (spread of disease), will be further explored by investigators at Rutgers Cancer Institute of New Jersey and the Ernest Mario School of Pharmacy at Rutgers University.A recently awarded $200,000 grant (R21CA185835) from the National Cancer Institute to researchers Suzie Chen, Ph.D., and James S. Goydos, M.D., FACS, will support the work.

Read More
MRV News
Melanoma News
Archive
Menu